Irlanda - engleză - HPRA (Health Products Regulatory Authority)

pliva pharma limited - topotecan hydrochloride - pdr/conc/soln for infus - 4 milligram

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - topotecan hydrochloride - solution for infusion - 1mg/1ml

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - topotecan hydrochloride - solution for infusion - 1mg/1ml

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - topotecan hydrochloride - pdr/conc/soln for infus - 4 milligram

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - topotecan hydrochloride - pdr/conc/soln for infus - 1 milligram

Canada - engleză - Health Canada

novartis pharmaceuticals canada inc - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - topotecan hydrochloride - concentrate for soln for inf - 1 mg/ml

Israel - engleză - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - hard gelatin capsules - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

Israel - engleză - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - hard gelatin capsules - topotecan as hydrochloride 1 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topotecan hydrochloride, quantity: 4 mg - injection, powder for - excipient ingredients: sodium hydroxide; tartaric acid; hydrochloric acid; mannitol - for single agent therapy for the treatment of patients with: small cell lung carcinoma, after failure of first line chemotherapy. metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. in combination with cisplatin for the treatment of patients with: histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.